FOOD AND DRUG ADMINISTRATION
Center for Drug Evaluation and Research
ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING

AGENDA

January 11, 2001

Holiday Inn – Bethesda, Maryland

Topic: Discuss clinical trial design issues for patients with HIV-1 infection who have limited therapeutic options (treatment sometimes referred to as "salvage" therapy).

8:30 a.m.	Call to Order/Welcome Introduction of Committee	Roy M. Gulick, M.D., M.P.H. Acting Chair, AVAC
8:35 a.m.	Conflict of Interest Statement	Tara P. Turner, Pharm.D. Executive Secretary, AVAC
8:45 a.m.	**Introduction/Opening Remarks**	Heidi Jolson, M.D., M.P.H. Director Division of Antiviral Drug Products, FDA
I.	**Trial Design Issues**	
9:00	**Therapeutic Challenges for Antiretroviral Experienced Patients: A Clinical Perspective**	Douglas Ward, M.D. DuPont Circle Physicians Group
9:15	**Overview of Trial Design Options: Adults**	Martin T. Schechter, M.D., Ph.D., FRCPC Professor, University of British Columbia National Director Canadian HIV Trials Network
9:45	**Overview of Trial Design Options: Pediatrics**	Coleen Cunningham, M.D. Associate Professor of Pediatrics SUNY Upstate Medical University
10:00	**Trial Design Options: Patient Perspective**	Carlton Hogan Community Programs for Clinical Research on AIDS (CPCRA) University of Minnesota School of Public Health Division of Biostatistics/CCBR
10:15	Break	
10:30	**The Study of Antiretroviral Agents in Heavily Pretreated HIV Infected Patients: A Regulatory Perspective**	Katherine Laessig, M.D. Division of Antiviral Drug Products, FDA

10:50 a.m. **Questions to the Committee**

1. What type of information would you most like to see from studies conducted in treatment experienced adults and children? Please comment on the use of studies in these populations to support efficacy for registration vs. their use for addressing more focused questions, such as drug interactions, dosing, or virologic response according to baseline susceptibility.

2. Please comment on the strengths and weaknesses of the trial design options presented.
3. What control arm(s) could be used for studies in this patient population?

   a. For placebo or no treatment controls, how long is it feasible to continue a randomized comparison? Please also comment on the clinical criteria for early switching from randomized therapy.
   b. What is the role of resistance testing for constructing background regimens?
   c. What constitutes an optimal background regimen?

4. Please comment on the advantages and disadvantages for conducting open-label studies instead of double-blind studies in this patient population.

12:00 Lunch

1:00 Open Public Hearing

Jim Rooney - ICC
Emmanuel Trenado
Dr. Vittecoq - EMEA, France
Michael Marco - Treatment Action Group
Otto Ah Ching, M.D. - Oxo Chemie AG

2:00 Continue Questions to the Committee

II. Endpoint Issues

2:45 p.m. **Response Rates in Heavily Pretreated HIV Infected Patients**
Roy M. Gulick, M.D., M..P.H.
Assistant Professor of Medicine
Weill Medical College of
Cornell University

3:15 p.m. **Statistical Considerations for Endpoints in Heavily Pretreated Patients**
Victor DeGruttola, Sc.D.
Professor of Biostatistics
Harvard School of Public Health

3:45 p.m. **Questions to the Committee**

5. What are the most appropriate study endpoints for trials in heavily pretreated patients? Please comment on the strengths and weaknesses of virologic, immunologic, and clinical Endpoints. In addition, please discuss the relevance of virologic endpoint metrics other than “below the limit of assay detection.”

6. Please discuss the role of shorter-term trials (e.g., 16 weeks) in assessing the safety and efficacy of new antiretrovirals in treatment-experienced patients. In your discussions, please consider the needs to establish long-term safety.

5:30 p.m. Adjourn

Antiviral Drugs Advisory Committee

January 11, 2001 Meeting

Consultants and Guests

Consultants (voting)

William Blackwelder, Ph.D. (Consultant – Center for Biologics Evaluation and Research)
8613 Hempstead Avenue
Bethesda, Maryland 20817

Michael Saag, M.D. (Consultant – Center for Biologics Evaluation and Research)
The University of Alabama at Birmingham
908 South 20th Street, CCB #178
Birmingham, AL 35294-2050

Patient Representatives (non-voting)

Lynda Dee, Baltimore, Maryland

Yvette Delph, Silver Spring, Maryland

Jules Levin, Brooklyn Heights, New York

Industry Guest (non-voting)

Ralph DeMasi, Ph.D.
Director of Biometrics
Trimeris, Inc.
4727 University Drive
Durham, North Carolina 27707

Antiviral Drugs Advisory Committee

January 11, 2001 Meeting

Guests and Guest Speakers (non-voting)

Coleen Cunningham, M.D.
SUNY HealthScience Center at Syracuse
Department of Pediatrics
Division of Infectious Diseases
750 East Adams Street
Syracuse, New York 13210-2306

Steven Deeks, M.D.
Assistant Clinical Professor of Medicine
Positive Health Program
Ward 84, Building 80
995 Potrero Avenue
San Francisco General Hospital
San Francisco, California 94110

Victor DeGruttola, Sc.D.
Professor of Biostatistics
Harvard School of Public Health
CBAR, Bldg. 2-439
677 Huntington Avenue
Boston, Massachusetts 02115

Joseph Eron, M.D.
547 Burnett Womack Building
CB#7030
University of North Carolina
Chapel Hill, North Carolina 27599

Judith Falloon, M.D.
National Institutes of Health
Building 10, Room 11C103
Bethesda, Maryland 20892-1880

Carlton Hogan
Community Programs for Clinical Research
on AIDS
University of Minnesota
Division of Biostatistics/CCBR
School of Public Health
2221 University Avenue, SE, Suite 200
Minneapolis, Minnesota 55414-3080

John Mellors, M.D.
Chief, Division of Infectious Diseases
Director, HIV/AIDS Program
University of Pittsburgh
Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, Pennsylvania 15261

Julio Montaner, M.D.
AIDS Research Program
St. Paul's Hospital
Room 667
1081 Burrard Street
Vancouver, BC, Canada V6Z 1Y6

Carla Pettinelli, M.D., Ph.D.
HIV Research Branch
Division of AIDS
National Institute of Allergy and Infectious Diseases
National Institutes of Health
6700-B Rockledge Drive
Room 5102
Bethesda, Maryland 20892-7620

Jonathan M. Schapiro, M.D.
Clinical Assistant Professor
Department of Medicine
Stanford University School of Medicine
Center for AIDS Research
S-156 Grant Building
Stanford, California 94305

Martin T. Schechter, M.D., Ph.D., FRCPC
CTN, St. Paul's Hospital
1081 Burrard Street
Vancouver, B.C., Canada V6Z 1Y6

Douglas Ward, M.D.
Dupont Circle Physicians Group
1737 20th Street, NW
Washington, DC 20009